Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04708301
Other study ID # 2014CD002
Secondary ID REC Reference No
Status Completed
Phase
First received
Last updated
Start date March 12, 2014
Est. completion date December 31, 2020

Study information

Verified date October 2021
Source Manchester University NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Fabry disease is a rare lysosomal storage disorder characterised by a genetic deficiency in the α-galactosidase enzyme. This deficiency leads to a progressive accumulation of a fatty substance, called glycosphingolipids within a specific part of our cells called the lysosome. This lysosomal accumulation can have devastating effects on patients with Fabry disease, affecting multiple organs. Heart involvement is particularly feared because it is the leading cause of death in Fabry disease. Cardiovascular magnetic resonance imaging (cardiac MRI) is a relatively new heart imaging technique. A cardiac MRI technique called T1 mapping can measure the magnetic relaxation properties of heart tissue. T1 mapping is important in Fabry disease because glycosphingolipids have distinct magnetic relaxation properties. The abnormal build up of glycosphingolipid within the heart may be detectable using T1 mapping. This accumulation of glycosphingolipid could identify an earlier form of Fabry disease. Moreover, it is postulated that T1 mapping may inform prognosis and response to therapy. Whilst promising, further investigation and development of this innovative technique in Fabry disease is required. This study aims to find out more about T1 mapping in Fabry disease. Patients referred for clinical cardiac MRI scanning will also undergo T1 mapping. T1 mapping results will be correlated with other markers of disease severity. This will allow heart muscle T1 to be determined in a larger population of Fabry patients than currently exists in the literature and T1 to be characterised across a wider range of Fabry disease severity than currently exists in the literature.


Description:

Anderson-Fabry disease (Fabry disease) is a genetic lysosomal storage disorder. Lysosomes are structures found within cells that contain enzymes which break down waste products and foreign material. In Fabry disease there is an inborn deficiency of an enzyme called α-galactosidase A. This leads to progressive accumulation of a fatty substance, called glycosphingolipid, in the lysosomes. Accumulation of glycosphingolipid in cells can affect the function of many organs, but in particular it affects the heart, the brain and nerves and the kidneys. It manifests as severe and chronic limb pain, progressive kidney dysfunction, transient ischaemic attacks and strokes, coronary artery disease and heart failure. Heart involvement is particularly important because it is responsible for the majority of deaths in patients with Fabry disease. Fabry disease affects between 1:17,000 to 1:117,000 people, although the prevalence is likely to be underestimated due to difficulties in diagnosis. It is seen across all ethnic and racial groups. It is a chronic disease with significantly reduced survival (median age of death 50). The culprit gene is carried on the X chromosome, therefore males are generally more severely affected than females, with symptoms beginning in childhood or adolescence. Manifestations are more variable in females, from no apparent disease to full expression, but up to 90% have symptoms. There is no cure for Fabry disease, however enzyme replacement therapy (ERT), which consists of providing affected patients with the deficient enzyme, is available. ERT has been demonstrated to reverse or slow disease progression before irreversible end-organ damage has occurred. However, there are no uniform guidelines as to which patients should receive ERT, when to start it, how to monitor response and when to stop it. As such, patient care is far from optimal, with patients who would benefit from ERT often getting it too late or potentially not getting it at all. Furthermore, ERT is being started in patients in whom the disease is irreversible, or continued in patients in whom it is no longer of benefit. As well as the implications for patient care, this has significant implications for healthcare provision, given that ERT costs in excess of £100,000 per patient per year. The reason why there are no good guidelines for ERT is that there is no good test to determine organ involvement or organ response to therapy. As explained above, heart involvement is particularly important but the current technique to assess heart involvement (ultrasound scanning of the heart (echocardiography)) is insensitive to accumulation of glycosphingolipid. Echocardiography allows assessment for heart muscle thickening and impairment of gross pumping function, but such changes occur late and are insensitive for assessing response to ERT. Heart muscle biopsy can determine glycosphingolipid accumulation, however this is very invasive, expensive and not an acceptable technique for this purpose. A non-invasive technique to detect early heart involvement in Fabry disease, that would guide initiation of ERT, monitor response to ERT and determine which patients will not benefit from ERT, is urgently required, both in terms of improving and individualizing patient care and in terms of optimizing healthcare provision. Cardiovascular magnetic resonance imaging (cardiac MRI) is a relatively new clinical heart imaging technique. It provides detailed and often unique information about heart structure and function. Cardiac MRI images are acquired using magnetic fields. It is free from ionizing radiation; indeed it is considered to be "one of the safest medical procedures currently available" (www.nhs.uk), and thus is an ideal technique for disease surveillance and treatment monitoring. One of the unique attributes of cardiac MRI is its ability to non-invasively characterise the make-up of heart muscle tissue. Just like all tissues have mass, all tissues have magnetic properties. A cardiac MRI technique called T1 mapping can measure the magnetic relaxation properties of tissues. T1 mapping techniques have been used to assess other organs for many years, but have only relatively recently been applied to the heart. Fat has different magnetic properties to heart muscle; specifically it has faster magnetic relaxation than heart muscle. This difference can be measured using T1 mapping - fat has a shorter (or lower value) T1 relaxation time than heart muscle. As described above, in Fabry disease, there is accumulation of glycosphingolipid in the heart. Also as described, glycosphingolipid is a fatty substance. Therefore, accumulation of this fat in the heart could theoretically be detected using the T1 mapping technique. Two small studies have demonstrated low T1 mapping values in Fabry disease patients in comparison to healthy volunteers and in comparison to patients with other heart conditions that cause heart muscle thickening (Sado et al Circ Cardiovasc Imaging. 2013;6:392-398 and Thompson et al Circ Cardiovasc Imaging. 2013;6:637-645). Interestingly, low T1 mapping values were seen in the absence of any other detectable changes in heart structure and function, suggesting that this technique could allow early detection of heart involvement in Fabry disease. T1 mapping and other allied cardiac MRI techniques (late gadolinium enhancement and extracellular volume quantification) have also been used to demonstrate heart muscle scarring in Fabry disease, which is irreversible and thus unlikely to be amenable to ERT. Potentially therefore, cardiac MRI T1 mapping could allow early detection of heart involvement in Fabry disease and thus better guide initiation of ERT, allow monitoring of heart response to ERT and, together with the allied cardiac MRI techniques described, determine when advanced disease is present and thus when ERT should be stopped or is not appropriate to initiate. Whilst promising, further investigation and development of this innovative technique in Fabry disease is required. This study aims to find out more about T1 mapping in Fabry disease. Patients referred for clinical cardiac MRI scanning will also undergo T1 mapping. T1 mapping results will be correlated with other markers of disease severity. This will allow: 1. Heart muscle T1 to be determined in a larger population of Fabry patients than currently exists in the literature 2. T1 to be characterised across a wider range of Fabry disease severity than currently exists in the literature.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients with Fabry disease Patients attending for a clinical cardiac MRI scan Exclusion Criteria: Patients who have a contraindication to cardiac MRI scanning (including pacemakers, defibrillators, intra-ocular metal, prohibitive intracranial aneurysm clips, severe claustrophobia, inability to lie flat).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
T1 mapping
T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map

Locations

Country Name City State
United Kingdom Manchester Univiersty Foundation Trust Manchester

Sponsors (2)

Lead Sponsor Collaborator
Manchester University NHS Foundation Trust Salford Royal NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial T1 relaxation time T1 time derived from myocardial T1 mapping through study completion, an average of 3 years
Secondary Left ventricular ejection fraction Derived from left ventricular volumetric cine imaging through study completion, an average of 3 years
Secondary Left ventricular mass Derived from left ventricular volumetric cine imaging through study completion, an average of 3 years
Secondary Right ventricular ejection fraction Derived from right ventricular volumetric cine imaging through study completion, an average of 3 years
Secondary Myocardial T2 relaxation time T2 time derived from myocardial T2 mapping through study completion, an average of 3 years
Secondary Adverse events Exploratory composite end-point of adverse events during follow-up Retrospective - data collection to be finalised by the end of February 2021
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Completed NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 Phase 1/Phase 2
Completed NCT01218659 - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Phase 3
Completed NCT00304512 - A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT03500094 - Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Phase 3
Withdrawn NCT04143958 - To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease Phase 4
Recruiting NCT02994303 - Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy N/A
Completed NCT01947634 - Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. N/A
Recruiting NCT01695161 - Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. N/A
Completed NCT01853852 - A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects Phase 1
Completed NCT00701415 - A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Phase 3
Completed NCT00068107 - Dosing Study of Replagal in Patients With Fabry Disease Phase 2
Completed NCT01997489 - Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Phase 4
Recruiting NCT06007768 - Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting NCT05698901 - Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Active, not recruiting NCT03305250 - Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease N/A
Terminated NCT00526071 - Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Phase 2
Active, not recruiting NCT03566017 - Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease Phase 3
Recruiting NCT06065605 - Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease